Klara Zakrzewska

The Maria Sklodowska-Curie National Research Institute of Oncology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Magdalena Chechlińska

The Maria Sklodowska-Curie National Research Institute of Oncology

Lukasz M. Szafron

The Maria Sklodowska-Curie National Research Institute of Oncology

Jan Konrad Siwicki

The Maria Sklodowska-Curie National Research Institute of Oncology

Mariusz Kulińczak

The Maria Sklodowska-Curie National Research Institute of Oncology

Maria Sromek

The Maria Sklodowska-Curie National Research Institute of Oncology

Anna Szumera‐Ciećkiewicz

The Maria Sklodowska-Curie National Research Institute of Oncology

Tomasz Tuziak

The University of Texas MD Anderson Cancer Center

Robert A. Wlodarczyk

The Maria Sklodowska-Curie National Research Institute of Oncology

Anna Mrozkowiak

The Maria Sklodowska-Curie National Research Institute of Oncology

Grzegorz Panek

Warsaw University of Technology

Cooperative Institutions

The Maria Sklodowska-Curie National Research Institute of Oncology

Centrum Onkologii

National Institute of Oncology

Medical University of Silesia

Wojewódzki Szpital Specjalistyczny nr 4 w Bytomiu

Children's Memorial Health Institute

Jagiellonian University

University of Warsaw

Postgraduate School of Molecular Medicine

European Organisation for Research and Treatment of Cancer

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection

Cellular Oncology (2017)

Maria Sromek Maciej Głogowski Magdalena Chechlińska Mariusz Kulińczak Lukasz M. Szafron

10.1007/s13402-017-0334-8

Cite

Citations (65)

Endometrial Cancer-Adjacent Tissues Express Higher Levels of Cancer-Promoting Genes than the Matched Tumors

Genes (2022)

Mariusz Kulińczak Maria Sromek Grzegorz Panek Klara Zakrzewska Renata Lotocka

Molecular alterations in tumor-adjacent tissues have recently been recognized in some types of cancer. This phenomenon has not been studied in endometrial cancer. We aimed to analyze the expression of genes associated with cancer progression and metabolism in primary endometrial cancer samples and the matched tumor-adjacent tissues and in the samples of endometria from cancer-free patients with uterine leiomyomas. Paired samples of tumor-adjacent tissues and primary tumors from 49 patients with endometrial cancer (EC), samples of endometrium from 25 patients with leiomyomas of the uterus, and 4 endometrial cancer cell lines were examined by the RT-qPCR, for MYC, NR5A2, CXCR2, HMGA2, LIN28A, OCT4A, OCT4B, OCT4B1, TWIST1, STK11, SNAI1, and miR-205-5p expression. The expression levels of MYC, NR5A2, SNAI1, TWIST1, and STK11 were significantly higher in tumor-adjacent tissues than in the matched EC samples, and this difference was not influenced by the content of cancer cells in cancer-adjacent tissues. The expression of MYC, NR5A2, and SNAI1 was also higher in EC-adjacent tissues than in samples from cancer-free patients. In addition, the expression of MYC and CXCR2 in the tumor related to non-endometrioid adenocarcinoma and reduced the risk of recurrence, respectively, and higher NR5A2 expression in tumor-adjacent tissue increased the risk of death. In conclusion, tissues proximal to EC present higher levels of some cancer-promoting genes than the matched tumors. Malignant tumor-adjacent tissues carry a diagnostic potential and emerge as new promising target of anticancer therapy.

SNAI1

Uterine cancer

Primary tumor

10.3390/genes13091611

Cite

Citations (7)

Her2, EGFR and TOPIIA gene amplification and protein expression in synovial sarcoma before and after combined treatment.

PubMed (2009)

Konrad Ptaszyński Anna Szumera‐Ciećkiewicz Klara Zakrzewska Tomasz Tuziak Anna Mrozkowiak

Synovial sarcoma (SyS) occurs mostly in young adults and is characterized by an aggressive course. Combined treatment including chemotherapy, radiotherapy and surgical excision of the tumour is still not satisfactory, with mean 5-year survival of 30-50%. New targeted treatment options have appeared recently, e.g. HER2 and EGFR antagonists. Initial studies have revealed immunohistochemical overexpression of the EGFR in SyS; therefore trials with EGFR antagonist therapy have commenced. The aim of our study was to evaluate the status of HER2, EGFR and TOPIIA in SyS before and after combined therapy. Immunohistochemistry and FISH tests were performed. Significant discrepancies between protein expression and gene status were found. The authors discuss the potential reasons for that phenomenon.

Synovial Sarcoma

Source

Cite

Citations (5)